Table 4 Percentage (%) distributions and odds ratios for receipt of radiation therapy among patients receiving definitive treatment (n = 2,347).
Characteristic | % | Crude 1 | OR (95% CI) | Adj.2 | OR (95% CI) | Adj.3 | OR (95% CI) |
|---|---|---|---|---|---|---|---|
| Â | Â | Â | Â | Model 1 | Model 2 | ||
Age-Race/ethnicity | Â | Â | Â | Â | Â | Â | Â |
Interaction4 | Â | Â | Â | Â | Â | Â | Â |
   <60, Non-Black |  | 1.00 | (referent) | 1.00 | (referent) |  |  |
   <60, NH Black |  | 2.98 | (1.77 - 4.96) | 2.62 | (1.50 - 4.52) |  |  |
   60-64, Non-Black |  | 2.01 | (1.42 - 2.88) | 1.95 | (1.36 - 2.83) |  |  |
   60-64, NH Black |  | 2.80 | (1.52 - 5.03) | 2.53 | (1.32 - 4.72) |  |  |
   65-74, Non-Black |  | 7.20 | (5.38 - 9.79) | 7.55 | (5.57 - 10.40) |  |  |
   65-74, NH Black |  | 5.14 | (3.24 - 8.18) | 5.19 | (3.15 - 8.59) |  |  |
   >= 75, Non-Black |  | 68.08 | (41.57 - 116.45) | 69.73 | (41.94 - 120.93) |  |  |
   >= 75, NH Black |  | 41.09 | (13.58 - 178.13) | 43.31 | (13.28 - 196.39) |  |  |
Age at diagnosis | Â | Â | Â | Â | Â | Â | Â |
   <60 | 17.20 | 1.00 | (referent) |  |  | 1.00 | (referent) |
   60-64 | 25.54 | 1.65 | (1.22 - 2.25) |  |  | 1.63 | (1.18 - 2.26) |
   65-69 | 39.76 | 3.18 | (2.41 - 4.22) |  |  | 3.37 | (2.52 - 4.54) |
   70-74 | 69.25 | 10.84 | (8.08 - 14.66) |  |  | 12.22 | (8.94 - 16.86) |
   >= 75 | 91.32 | 50.63 | (32.27 - 82.56) |  |  | 54.47 | (34.11 - 90.27) |
Marital status | Â | Â | Â | Â | Â | Â | Â |
   Married | 42.30 | 1.00 | (referent) | 1.00 | (referent) | 1.00 | (referent) |
   Not Married | 49.18 | 1.32 | (1.05 - 1.65) | 1.44 | (1.10 - 1.88) | 1.51 | (1.15 - 1.98) |
   Unknown | 60.58 | 2.10 | (1.41 - 3.16) | 2.20 | (1.36 - 3.58) | 2.22 | (1.36 - 3.65) |
Registry | Â | Â | Â | Â | Â | Â | Â |
   California | 36.60 | 1.00 | (referent) | 1.00 | (referent) | 1.00 | (referent) |
   Colorado | 39.30 | 1.12 | (0.83 - 1.52) | 1.57 | (1.10 - 2.25) | 1.60 | (1.11 - 2.31) |
   Illinois | 46.46 | 1.50 | (1.11 - 2.04) | 1.57 | (1.09 - 2.27) | 1.71 | (1.17 - 2.49) |
   Louisiana | 38.36 | 1.08 | (0.80 - 1.46) | 1.06 | (0.73 - 1.53) | 1.07 | (0.74 - 1.56) |
   New York | 53.80 | 2.02 | (1.49 - 2.75) | 2.40 | (1.66 - 3.49) | 2.78 | (1.91 - 4.06) |
   Rhode Island | 49.39 | 1.69 | (1.24 - 2.30) | 2.00 | (1.39 - 2.90) | 1.98 | (1.36 - 2.89) |
   South Carolina | 47.66 | 1.58 | (1.14 - 2.19) | 2.12 | (1.43 - 3.14) | 2.35 | (1.58 - 3.51) |
DRE results | Â | Â | Â | Â | Â | Â | Â |
   Normal | 40.28 | 1.00 | (referent) | 1.00 | (referent) | 1.00 | (referent) |
   Abnormal | 50.67 | 1.52 | (1.26 - 1.84) | 1.19 | (0.95 - 1.50) | 1.17 | (0.93 - 1.48) |
   Equivocal/unknown | 41.33 | 1.05 | (0.85 - 1.29) | 0.78 | (0.60 - 1.02) | 0.77 | (0.59 - 1.00) |
PSA value | Â | Â | Â | Â | Â | Â | Â |
   0-4 | 39.52 | 1.00 | (referent) | 1.00 | (referent) | 1.00 | (referent) |
   >4-10 | 41.56 | 1.09 | (0.81 - 1.47) | 1.01 | (0.71 - 1.44) | 1.06 | (0.74 - 1.53) |
   >10-20 | 53.88 | 1.79 | (1.28 - 2.50) | 1.57 | (1.06 - 2.34) | 1.64 | (1.09 - 2.46) |
   20+ | 61.00 | 2.40 | (1.61 - 3.58) | 2.14 | (1.34 - 3.45) | 2.17 | (1.35 - 3.52) |
   Unknown | 29.91 | 0.65 | (0.44 - 0.97) | 0.45 | (0.27 - 0.73) | 0.46 | (0.28 - 0.75) |
Gleason score | Â | Â | Â | Â | Â | Â | Â |
   2-4 | 43.01 | 1.00 | (referent) | 1.00 | (referent) | 1.00 | (referent) |
   5-7 | 40.92 | 0.92 | (0.68 - 1.24) | 0.76 | (0.54 - 1.09) | 0.76 | (0.53 - 1.09) |
   8-10 | 61.05 | 2.08 | (1.39 - 3.13) | 1.53 | (0.94 - 2.48) | 1.59 | (0.97 - 2.62) |
   Unknown | 72.48 | 3.49 | (2.12 - 5.86) | 5.59 | (3.09 - 10.34) | 5.64 | (3.08 - 10.52) |